Important Safety Information
CUROSURF® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.
CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.
Transient adverse reactions associated with administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.
Pulmonary hemorrhage, a known complication of premature birth and very low birth-weight, has been reported with CUROSURF. The rates of common complications of prematurity observed in a multicenter single-dose study that enrolled infants 700–2000 g birth weight with RDS requiring mechanical ventilation and FiO2 ≥ 0.60 are as follows for CUROSURF 2.5 mL/kg (200 mg/kg) (n=78) and control (n=66; no surfactant) respectively: acquired pneumonia (17% vs. 21%), acquired septicemia (14% vs. 18%), bronchopulmonary dysplasia (18% vs. 22%), intracranial hemorrhage (51% vs. 64%), patent ductus arteriosus (60% vs. 48%), pneumothorax (21% vs. 36%) and pulmonary interstitial emphysema (21% vs. 38%).
CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.
Please see accompanying full prescribing information.
References: 1. IMS DDD Lung Surfactant Market Purchases May 2004 to December 2011. 2. CUROSURF® (poractant alfa) Intratracheal Suspension Prescribing Information, Chiesi USA, Inc. December 2014. 3. Survanta® (beractant) Intratracheal Suspension Prescribing Information, AbbVie, Inc. December 2012. 4. Infasurf® (calfactant) Intratracheal Suspension Prescribing Information, ONY, Inc, June 2011. 5. Gerdes JS, Seiberlich W, Sivieri EM, et al. J Pediatr Pharmacol Ther. 2006;11:92-100. 6. Wiseman LR, Bryson HM. Drugs. 1994;48:386-403. 7. Collaborative European Multicenter Study Group. Pediatrics. 1988;82:683-691. 8. Speer CP, Gefeller O, Groneck P, et al. Arch Dis Child.1995;72:F8-F13. 9. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; And The North American Study Group. Am J Perinatol. 2004;21:109-119. 10. Dizdar EA, Sari FN, Aydemir C, et al. Am J Perinatol. 2012;29(2):95-100. 11. Sandri F, Plavka R, Ancora G, et al. Pediatrics. 2010;125:1402-1409. 12. Dani C, Bertini G, Pezzati M, et al.Pediatrics. 2004;113:e560-e563. 13. Verder H, Albertsen P, Ebbesen F, et al. Pediatrics. 1999;103:1-6.